Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Oncology Drugs Market, by Indication
1.4.2 Europe Oncology Drugs Market, by Drug Class Type
1.4.3 Europe Oncology Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar – 2023, Nov) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. Europe Oncology Drugs Market by Indication
5.1 Europe Breast Cancer Market by Country
5.2 Europe Prostate Cancer Market by Country
5.3 Europe Lung Cancer Market by Country
5.4 Europe Stomach Cancer Market by Country
5.5 Europe Colorectal Cancer Market by Country
5.6 Europe Liver Cancer Market by Country
5.7 Europe Esophagus Cancer Market by Country
5.8 Europe Cervical Cancer Market by Country
5.9 Europe Kidney Cancer Market by Country
5.10. Europe Bladder Cancer Market by Country
5.11 Europe Other Cancer Market by Country
Chapter 6. Europe Oncology Drugs Market by Drug Class Type
6.1 Europe Targeted Therapy Market by Country
6.2 Europe Immunotherapy (Biologic Therapy) Market by Country
6.3 Europe Chemotherapy Market by Country
6.4 Europe Hormonal Therapy Market by Country
Chapter 7. Europe Oncology Drugs Market by Country
7.1 Germany Oncology Drugs Market
7.1.1 Germany Oncology Drugs Market by Indication
7.1.2 Germany Oncology Drugs Market by Drug Class Type
7.2 UK Oncology Drugs Market
7.2.1 UK Oncology Drugs Market by Indication
7.2.2 UK Oncology Drugs Market by Drug Class Type
7.3 France Oncology Drugs Market
7.3.1 France Oncology Drugs Market by Indication
7.3.2 France Oncology Drugs Market by Drug Class Type
7.4 Russia Oncology Drugs Market
7.4.1 Russia Oncology Drugs Market by Indication
7.4.2 Russia Oncology Drugs Market by Drug Class Type
7.5 Spain Oncology Drugs Market
7.5.1 Spain Oncology Drugs Market by Indication
7.5.2 Spain Oncology Drugs Market by Drug Class Type
7.6 Italy Oncology Drugs Market
7.6.1 Italy Oncology Drugs Market by Indication
7.6.2 Italy Oncology Drugs Market by Drug Class Type
7.7 Rest of Europe Oncology Drugs Market
7.7.1 Rest of Europe Oncology Drugs Market by Indication
7.7.2 Rest of Europe Oncology Drugs Market by Drug Class Type
Chapter 8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Amgen, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.5.5.3 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental & Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional & Segmental Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.6 SWOT Analysis
Unique Offerings 